Retatrutide vs Tirzepatide — Research Comparison

Retatrutide and tirzepatide are both long-acting incretin-class research peptides that move beyond GLP-1 mono-agonism, but they differ in the number of receptors engaged. Tirzepatide is a GLP-1 + GIP dual agonist; retatrutide adds glucagon to make a GLP-1 + GIP + glucagon triple agonist. This comparison summarises the published literature relevant to laboratory research.

At-a-glance comparison

| Attribute | Retatrutide | Tirzepatide | |---|---|---| | Receptor target | GLP-1 + GIP + Glucagon | GLP-1 + GIP | | Class | Triple incretin agonist | Dual incretin agonist | | Reported half-life | ~6 days | ~5 days | | Cited weight-loss in Phase 2/3 trials | ~24% at 48 weeks | ~22.5% at 72 weeks | | Energy expenditure | Increased (glucagon arm) | Neutral | | Published trial program | TRIUMPH | SURPASS / SURMOUNT | | Approval status (research-literature note) | Phase 3 | Approved for type-2 diabetes and obesity |

Mechanism — the glucagon arm

Tirzepatide's dual GLP-1 + GIP agonism is most cited in the literature for combined insulinotropic, gastric-emptying and appetite-suppression effects. Retatrutide retains both of these arms and adds glucagon-receptor agonism, which is associated in published rodent and Phase 2 human data with increased hepatic glucose output and lipolysis, producing a net increase in energy expenditure rather than hyperglycaemia in the published trials.

Pharmacokinetics

Both compounds are fatty-acid-conjugated peptides engineered for once-weekly subcutaneous dosing. Tirzepatide's reported half-life is approximately 5 days; retatrutide's is approximately 6 days. Both demonstrate dose-proportional exposure across the studied range.

Published research highlights

Tirzepatide's research base is the SURPASS (type-2 diabetes) and SURMOUNT (obesity) programs, with mean body-weight reduction up to approximately 22.5% in SURMOUNT-1 at 72 weeks. Retatrutide's TRIUMPH-2 Phase 2 trial reported approximately 24% mean body-weight reduction at 48 weeks at the 12 mg weekly dose. Cross-trial comparisons should be interpreted cautiously.

Where they overlap, where they don't

Overlap: GLP-1 and GIP-receptor agonism, once-weekly dosing, dose-proportional exposure. Divergence: retatrutide's glucagon arm is associated with measurable increases in resting energy expenditure that tirzepatide does not produce; tirzepatide has a much larger published cardiovascular-research dataset.

Choosing one for a research protocol

For research into dual GLP-1 + GIP biology, mature cardiovascular comparator data, or the most-studied incretin-research dataset, tirzepatide is the more-referenced compound. For research into triple-receptor incretin combinations, energy-expenditure mechanisms, or maximum cited weight-loss magnitudes in current literature, retatrutide is the more current reference.

Frequently asked research questions

Is retatrutide essentially tirzepatide plus glucagon?

Mechanistically retatrutide adds the glucagon-receptor arm to the dual GLP-1 + GIP target profile of tirzepatide. The molecules themselves are different fatty-acid-conjugated peptides with different sequences and balanced potencies across the three receptors.

Do they differ in gastrointestinal side-effect profile?

Both compounds report dose-dependent GI side effects in published trials (nausea, diarrhoea, constipation). The published rates are broadly comparable per-dose and decrease with titration.

Which compound has more long-term human-research data?

Tirzepatide has substantially more published long-term human-research data because it has been in trials longer. Retatrutide's published data is concentrated in shorter-duration Phase 2 trials at the time of writing.

Can the two be used together?

Combination use is not described in the published literature and would be redundant — both already engage GLP-1 and GIP. There is no published research model that combines them.

Related research

• Retatrutide research hub → /research/hubs/retatrutide
• Tirzepatide research hub → /research/hubs/tirzepatide
• Semaglutide research hub → /research/hubs/semaglutide
• Retatrutide vs Semaglutide → /research/retatrutide-vs-semaglutide-research-comparison

Research use only. All content on this page is provided for in-vitro and laboratory research purposes. No statements are intended for, and nothing on this page should be construed as, medical advice or a recommendation for human consumption.